APPLICATION
ANDA210748
TYPE
ANDA
ORIGINAL APPROVAL
2019-02-27
LATEST ACTION
2025-01-24
ROUTE
INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued
Products
AZACITIDINEDiscontinued
AZACITIDINE 100MG/VIAL · POWDER · INTRAVENOUS, SUBCUTANEOUS
Approval history
2025-01-24Labeling · Supplement 3 · standardAP
2023-09-19Labeling · Supplement 1 · standardAP
2023-09-19Labeling · Supplement 2 · standardAP
2019-02-27UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.